Skip to content
OpenCapital
Get started

TransMedics Group, Inc. TMDX Q1 2026 earnings

Reported May 5, 2026 · After market close

Revenue$173.9MMiss by $503.3K
EPS$0.30Miss by $0.32
Revenue estimate$174.4M
EPS estimate$0.62

Next report

Aug 4, 2026 (In 6 days)
Revenue estimate$183.8M
EPS estimate$0.50

Financials

Q1 2026

Income statement

See full
Revenue$173.9M+21.2%
Gross profit$101.2M+14.7%
Operating income$13.3M-51.5%
Net income$7.3M-71.5%
EPS (diluted)$0.20-71.4%

Balance sheet

See full
Cash & equivalents$461.7M+48.9%
Total debt$409.9M+505%
Total equity$494.0M+85.5%
Total assets$1.4B+71.3%

Cash flow

See full
Operating cash flow$24.5M+959%
CapEx$36.7M+35.6%
Free cash flow-$12.1M+59.4%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$2.57B-27.9%
Enterprise value$2.52B-22.1%
P/E14.9×-34.7×
P/S4×-2.7×

Profitability

See full
Gross margin59.1%-0.4pp
Operating margin14.9%+4.1pp
Net margin27%+17.0pp
FCF margin23.8%—

Returns & leverage

See full
Return on equity45.2%+22.2pp
Debt / equity0.8×+0.6×
Current ratio6.7×-2.4×

Segments

By product

See full
Liver Product$139.0M+27.7%
Heart Product$30.9M+3.5%
Lung Product$2.8M-29.6%

By segment

See full
Ocs Transplant Revenue$172.7M+21.0%

By geography

See full
Non Us$5.6M—

Versus estimates

Revenue

Q1 2026$173.9MMiss by $503.3K
Q4 2025$160.8MBeat by $5.4MQ3 2025$143.8MMiss by $11.6MQ2 2025$157.4MBeat by $15.7MQ1 2025$143.5MBeat by $20.1MQ4 2024$121.6MBeat by $12.1M

Diluted EPS

Q1 2026$0.30Miss by $0.32
Q4 2025$0.57Beat by $0.16Q3 2025$0.66Beat by $0.29Q2 2025$0.92Beat by $0.44Q1 2025$0.70Beat by $0.41Q4 2024$0.19Miss by $0.03

Ask the moment TransMedics Group, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did TransMedics Group, Inc. report Q1 2026 earnings?
TransMedics Group, Inc. (TMDX) reported Q1 2026 earnings on May 5, 2026 after market close.
What were TransMedics Group, Inc.'s Q1 2026 revenue and EPS?
TransMedics Group, Inc. reported revenue of $173.9M and eps of $0.30 for Q1 2026.
Did TransMedics Group, Inc. beat estimates in Q1 2026?
Revenue missed the consensus estimate of $174.4M by $503.3K. EPS missed the consensus estimate of $0.62 by $0.32.
How did TransMedics Group, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 21.2% from $143.5M a year earlier and eps declined 57.1% from $0.70.
Where can I find TransMedics Group, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-206347) and the 10-Q periodic report (0001193125-26-206453) directly on SEC EDGAR. The filing index links above go to sec.gov.